Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01262456
Recruitment Status : Completed
First Posted : December 17, 2010
Results First Posted : October 15, 2015
Last Update Posted : October 15, 2015
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals

Tracking Information
First Submitted Date  ICMJE December 15, 2010
First Posted Date  ICMJE December 17, 2010
Results First Submitted Date  ICMJE June 18, 2015
Results First Posted Date  ICMJE October 15, 2015
Last Update Posted Date October 15, 2015
Study Start Date  ICMJE February 2011
Actual Primary Completion Date January 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 16, 2015)
  • Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period [ Time Frame: Day 1 (Baseline), Week 1, Months 1, 2, 3 (3-month double-blind treatment period) ]
    The number of nocturnal voids was the average over 3 consecutive 24-hour periods prior to Day 1 and prior to the during-treatment visits (Week 1, Months 1, 2, 3) as recorded in participant diaries. The first morning void was not counted as a nocturnal void. Change from baseline values for Week 1, and Months 1, 2 and 3 are reported below. Comparison of the mean number of nocturnal voids at baseline and over a 3-month treatment period (obtained by longitudinal analysis of Week 1, and Months 1, 2 and 3) are reported in the statistical analysis. This was the first co-primary outcome. Superiority to placebo was to be simultaneously demonstrated on the 2 co-primary outcomes in a step-down approach from highest (75 μg) to lowest dose (50 μg), thereby controlling the family-wise error rate at the 5% nominal significance level.
  • Adjusted Probability of Participants Achieving a >33% Reduction From Baseline in Number of Nocturnal Voids for All During-Treatment Visits up to Month 3 [ Time Frame: Day 1 (Baseline), Week 1, Months 1, 2, 3 (3-month double-blind treatment period) ]
    Probability of participants achieving 33% responder status during 3 months of treatment employed a longitudinal analysis assessing nocturnal void information captured in the 3-day diary. A 33% responder was defined as a participant with a decrease of at least 33% in the mean number of nocturnal voids relative to baseline. The number of nocturnal voids was the average over 3 consecutive 24-hour periods prior to Day 1 and prior to the during treatment visits (Week 1, Months 1, 2, 3) as recorded in participant diaries. The first morning void was not counted as a nocturnal void. This was the second co-primary outcome. Superiority to placebo was to be simultaneously demonstrated on the 2 co-primary endpoints in a step-down approach from highest (75 μg) to lowest dose (50 μg), thereby controlling the family-wise error rate at the 5% nominal significance level.
Original Primary Outcome Measures  ICMJE
 (submitted: December 16, 2010)
  • Reduction of mean number nocturnal voids relative to baseline [ Time Frame: 3 months of treatment compared to Baseline ]
  • A decrease of at least 33% in the mean number of nocturnal voids [ Time Frame: 3 months of treatment compared to Baseline ]
  • Reduction of mean number nocturnal voids relative to baseline [ Time Frame: 4 months of treatment compared to Baseline ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 16, 2015)
  • Change From Baseline in Mean Number of Nocturnal Voids at Month 3 [ Time Frame: Day 1 (Baseline), Month 3 ]
    Comparison of the mean number of nocturnal voids at baseline and at the 3-month visit. The number of nocturnal voids was the average over 3 consecutive 24-hour periods prior to the relevant visits as recorded in participant diaries. The first morning void was not counted as a nocturnal void. The secondary efficacy outcomes (#3-7) used a hierarchical step-down approach in the order listed. The active treatment groups were compared to placebo using a step-down approach from highest dose (75 µg) to lowest dose (50 µg).
  • Adjusted Probability of Participants Achieving a >33% Reduction From Baseline in Number of Nocturnal Voids at Month 3 [ Time Frame: Day 1 (Baseline), Month 3 ]
    Probability of participants achieving 33% responder status at Month 3 employed a longitudinal analysis assessing nocturnal void information captured in the 3-day diary. A 33% responder was defined as a participant with a decrease of at least 33% in the mean number of nocturnal voids relative to baseline. The number of nocturnal voids was the average over 3 consecutive 24-hour periods prior to Day 1 and prior to the Month 3 visit as recorded in participant diaries. The first morning void was not counted as a nocturnal void. The secondary efficacy outcomes (#3-7) used a hierarchical step-down approach in the order listed. The active treatment groups were compared to placebo using a step-down approach from highest dose (75 µg) to lowest dose (50 µg).
  • Change From Baseline in Mean Time to First Nocturnal Void at Month 3 [ Time Frame: Day 1 (Baseline), Month 3 ]
    The time to first void was defined as the time from going to bed with the intention of sleeping until first nocturnal void or until waking in the morning in the case where there was no nocturnal void. The first morning void was not counted as a nocturnal void. The time to first void was derived from the sleep and voiding diary. The mean time to first void was calculated as the average over 3 consecutive 24-hour periods prior to the Month 3 visit. The secondary efficacy outcomes (#3-7) used a hierarchical step-down approach in the order listed. The active treatment groups were compared to placebo using a step-down approach from highest dose (75 µg) to lowest dose (50 µg).
  • Change From Baseline in Nocturnal Urine Volume at Month 3 [ Time Frame: Day 1 (Baseline), Month 3 ]
    The nocturnal urine volume was derived from the 3-day urine volume diary. The nocturnal urine volume included the volume of the first morning void. Mean urine volumes were calculated as the average over 3 consecutive 24-hour periods prior to the Month 3 visit. The secondary efficacy outcomes (#3-7) used a hierarchical step-down approach in the order listed. The active treatment groups were compared to placebo using a step-down approach from highest dose (75 µg) to lowest dose (50 µg).
  • Change From Baseline in 24-Hour Urine Volume at Month 3 [ Time Frame: Day 1 (Baseline), Month 3 ]
    Twenty-four hour urine volume was derived from the 3-day urine volume diary. Mean urine volumes were calculated as the average over 3 consecutive 24-hour periods prior to the Month 3 visit. The secondary efficacy outcomes (#3-7) used a hierarchical step-down approach in the order listed. The active treatment groups were compared to placebo using a step-down approach from highest dose (75 µg) to lowest dose (50 µg).
  • Summary of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Period [ Time Frame: From Day 1 through Month 3 (double-blind period) ]
    A TEAE was any adverse event (AE) occurring after start of treatment and within the time of residual drug effect, i.e., within 1 day for desmopressin. An adverse drug reaction (ADR) was any AE assessed by the investigator as possibly or probably related to study drug.
  • Summary of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Period [ Time Frame: Month 1 of open-label period (Month 4 of treatment) ]
    A TEAE was any adverse event (AE) occurring after start of treatment and within the time of residual drug effect, i.e., within 1 day for desmopressin. An adverse drug reaction (ADR) was any AE assessed by the investigator as possibly or probably related to study drug.
  • Minimum Post-Treatment Serum Sodium Levels in the Double-Blind Period [ Time Frame: Day 1 through Month 3 (double-blind period) ]
    Serum sodium levels were monitored at each study visit since hyponatremia is a potential serious adverse event associated with daily doses of desmopressin. The serum sodium level must have been within the normal reference range at the Screening Visit for the participant to be eligible for enrollment. A participant was to be withdrawn from the trial if the serum sodium level was <=125 mmol/L at any time.
  • Minimum Post-Treatment Serum Sodium Levels in the Open-Label Period [ Time Frame: Month 1 of open-label period (Month 4 of treatment) ]
    Serum sodium levels were monitored at each study visit since hyponatremia is a potential serious adverse event associated with daily doses of desmopressin. The serum sodium level must have been within the normal reference range at the Screening Visit for the participant to be eligible for enrollment. A participant was to be withdrawn from the trial if the serum sodium level was <=125 mmol/L at any time.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 16, 2010)
  • Reduction mean number of night voids based on the three-days diary [ Time Frame: 3 months of treatment compared to Baseline ]
  • Change in time to first void based on the three-days diary [ Time Frame: 3 months of treatment compared to Baseline ]
  • Change in nocturnal urine volume and 24-hour urine volume based on the three-days diary [ Time Frame: 3 months of treatment compared to Baseline ]
  • Incidence of hyponatraemia as measured by serum sodium level throughout the trial [ Time Frame: from end of the first week up to three months in Double-blind part ]
  • Incidence of hyponatraemia as measured by serum sodium level throughout the trial [ Time Frame: from end of the first week up to one month in Open-label part ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
Official Title  ICMJE A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablets for the Treatment of Nocturia in Adult Males
Brief Summary The purpose of this trial was to confirm/establish long-term safety and efficacy of desmopressin orally disintegrating tablets at dose levels of 50 μg and 75 μg and to further evaluate the safety of an efficacious higher dose level of 100 μg in males with nocturia.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Nocturia
Intervention  ICMJE
  • Drug: Desmopressin
    Other Names:
    • FE992026
    • MINIRIN®
    • Nocturin®
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: Desmopressin 50 μg Double-Blind / 100 μg Open-Label
    Participants took 1 orally disintegrating tablet of desmopressin 50 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
    Intervention: Drug: Desmopressin
  • Experimental: Desmopressin 75 μg Double-Blind / 100 μg Open-Label
    Participants took 1 orally disintegrating tablet of desmopressin 75 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
    Intervention: Drug: Desmopressin
  • Placebo Comparator: Placebo Double-Blind / Desmopressin 100 μg Open-Label
    Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
    Interventions:
    • Drug: Desmopressin
    • Drug: Placebo
Publications * Weiss JP, Herschorn S, Albei CD, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013 Sep;190(3):965-72. doi: 10.1016/j.juro.2012.12.112. Epub 2013 Feb 20.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 16, 2015)
395
Original Estimated Enrollment  ICMJE
 (submitted: December 16, 2010)
390
Actual Study Completion Date  ICMJE January 2012
Actual Primary Completion Date January 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Written informed consent prior to performance of any trial-related activity
  • Male sex 18 years of age or older
  • At least 2 voids every night in a consecutive 3-day period during the screening period based on the patient diary.

Exclusion Criteria:

  • Evidence of severe daytime voiding dysfunction defined as: Urge urinary incontinence (more than 1 episode/day in the 3-day diary period), Urgency (more than 1 episode/day in the 3-day diary period), Frequency (more than 8 daytime voids/day in the 3-day diary period)
  • Interstitial Cystitis
  • Chronic prostatitis/chronic pelvic pain syndrome
  • Suspicion of bladder outlet obstruction (BOO) or a urine flow of less than 5 mL/s as confirmed by uroflowmetry performed after suspicion of BOO
  • Surgical treatment, including transurethral resection, for BOO or benign prostatic hyperplasia within the past 6 months
  • Urinary retention or a post void residual volume in excess of 250 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention
  • Habitual or psychogenic fluid intake resulting in a urine production exceeding 40 mL/kg/24 hours
  • Central or nephrogenic diabetes insipidus.
  • Syndrome of inappropriate anti-diuretic hormone.
  • Current or a history of urologic malignancies e.g. urothelium, prostate, or kidney cancer
  • Genitourinary tract pathology e.g. infection or stone in the bladder and urethra causing symptoms
  • Neurogenic detrusor activity (detrusor overactivity)
  • Suspicion or evidence of cardiac failure
  • Uncontrolled hypertension
  • Uncontrolled diabetes mellitus
  • Hyponatraemia: Serum sodium level must be within normal limits
  • Renal insufficiency: Serum creatinine must be within normal limits and estimated glomerular filtration rate must be more than or equal to 50 mL/min
  • Hepatic and/or biliary diseases: Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels must not be more than twice the upper limit of normal range. Total bilirubin level must not be more than 1.5 mg/dL
  • History of obstructive sleep apnea
  • Previous desmopressin treatment for nocturia
  • Treatment with another investigational product within 3 months prior to screening
  • Concomitant treatment with any prohibited medication, i.e. loop diuretics (furosemide, torsemide, ethacrynic acid) and any other investigational drug
  • Known alcohol or substance abuse
  • Work or lifestyle that may interfere with regular nighttime sleep e.g. shift workers
  • Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01262456
Other Study ID Numbers  ICMJE FE992026 CS41
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Ferring Pharmaceuticals
Study Sponsor  ICMJE Ferring Pharmaceuticals
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Development Support Ferring Pharmaceuticals
PRS Account Ferring Pharmaceuticals
Verification Date September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP